The use of point-of-care testing (POCT) to make rapid treatment decisions is becoming increasingly popular in order to achieve greater efficiency and improve patient pathways.
The ABX Micros ES60 haematology analyser from HORIBA Medical provides a fast, laboratory standard full blood count, with a 3-part differential in a variety of POC settings. Combining ease of use with CPA compliance, it is ideal for use within the POCT environment and has been scientifically proven to enable effective therapeutic drug monitoring.
With a small workspace footprint, fitting neatly onto the bench top, the ABX Micros ES60 is specifically designed for specialist clinics and point of care situations, including A&E and oncology, where a fast turnaround of haematology results can make a real difference to patient waiting times and outcomes. Processing up to 60 samples an hour, the ABX Micros ES60 can handle micro-samples (10µL) in open and closed tube versions, processing 18 parameters, CBCs as well as 3-part differential analysis.
The ABX Micros ES60 encompasses all the functions needed to achieve CPA compliance and manage results securely. The integral touch screen with virtual keyboard provides control of all analysis parameters and access to detailed patient results on a large full colour display. The operating system has capacity for 1000 patient results and USB connectivity gives the option for downloading QC target values, as well as archiving valuable and QC reports. For added convenience, an integrated ticket printer produces full data print-outs, including PLT, RBC and WBC curves. Finally, for ease of use, an integrated barcode reader provides secure identification of patient samples, QC and reagents to prevent data transcription errors and speed up workflow.
Effective therapeutic drug monitoring
A recent study undertaken by scientists at the University Hospital of Wales in Cardiff in collaboration with HORIBA Medical specialists, has confirmed that the granulocyte count of the ABX Micros ES60 correlates well when compared to the neutrophil count of a 5-part differential analyser, in the absence of specific flagging. This suggests that the ABX Micros ES60 granulocyte count can be confidently taken as the neutrophil count in therapeutic drug monitoring, provided that no M2 alarms are triggered. The neutrophil count is a key parameter in determining the treatment outcomes, with regards to chemotherapy, for both oncology and haematology patients, as well as for some other drug therapies, such as Clozapine.
To download a poster of this study please visit: http://www.horiba.com/uk/medical/feedback/poc-case-study-abx-micros-es-60
